FCGR2A and cancer: Single nucleotide polymorphisms (SNPs) of FcγR can alter ligand binding (e.g. by changing the affinity of FcγR for a particular IgG subclass), affect receptor function or modify its level of expression, and directly impact the effectiveness of immune response for mAb-based regimens in cancer patients (10).